UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code:
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading |
Name of each exchange | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
On August 20, 2024, Aileron Therapeutics, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders to consider and vote upon the matters listed below. The following is a summary of the matters voted on at that meeting.
1. | The stockholders of the Company elected Brian Windsor, Ph.D. and Alan A. Musso as Class I directors for a three-year term expiring at the 2027 Annual Meeting of Stockholders. The results of the stockholders’ vote with respect to such matter were as follows: |
Name | For |
Withheld |
Broker | |||
Brian Windsor, Ph.D. |
7,828,121 | 24,847 | 3,442,389 | |||
Alan A. Musso |
7,828,044 | 24,924 | 3,442,389 |
2. | The stockholders of the Company approved, on a non-binding advisory basis, the Company’s named executive officer compensation. The results of the stockholders’ vote with respect to such matter were as follows: |
For |
Against |
Abstain |
Broker | |||||||||
7,326,953 |
109,458 | 416,557 | 3,442,389 |
3. | The stockholders of the Company ratified the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. The results of the stockholders’ vote with respect to such matter were as follows: |
For |
Against |
Abstain | ||||||
10,817,251 |
61,696 | 416,410 |
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. | Description | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL Document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AILERON THERAPEUTICS, INC. | ||||||
Date: August 21, 2024 | By: | /s/ Brian Windsor | ||||
Brian Windsor, Ph.D. | ||||||
President and Chief Executive Officer |